source
- Pfizer reports flat Q3 revenue as non-COVID sales rise 7% and acquired products grow 32%Pfizer posted third‑quarter revenue of $16.6 billion, essentially unchanged from $16.7 billion a year earlier. The flat top line reflects declines in its legacy Prevnar vaccine and COVID‑related pr…
- UniQure slated for FDA decision by May 1 as analysts see potential for first Huntington’s disease therapyUniQure said the Food and Drug Administration has set a decision date for its Huntington's disease gene therapy and is likely to hold an advisory committee meeting. The agency indicated a faster‑th…